KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, Fiorentino M, Porcellini E, Buoro V, Gelsomino F, Squadrilli A, Fasola G, Negrini M, Tiseo M, Ferracin M, Ardizzoni A.
Cinausero M, et al. Among authors: ferracin m.
Ther Adv Med Oncol. 2019 Nov 14;11:1758835919885540. doi: 10.1177/1758835919885540. eCollection 2019.
Ther Adv Med Oncol. 2019.
PMID: 31798692
Free PMC article.